Trial ID or NCT#



not recruiting iconNOT RECRUITING


This open-label, rater-blinded extension study enrolled participants who had relapsing-remitting multiple sclerosis (RRMS) and who participated in one of three prior Genzyme-sponsored studies of alemtuzumab (CAMMS223 [NCT00050778], CAMMS323 [NCT00530348] also known as CARE-MS I, or CAMMS324 [NCT00548405] also known as CARE-MS II). The purposes of this study were: 1. To examine the long term safety and efficacy of alemtuzumab treatment in participants who received alemtuzumab as their study treatment in one of the prior studies. 2. To examine the safety and efficacy of initial alemtuzumab treatment in this study for participants who received Rebif® (interferon beta-1a) as their study treatment in one of the prior studies. 3. To determine the safety and efficacy of additional "as needed" alemtuzumab treatment courses. This applied both to participants who received alemtuzumab for the first time in one of the prior studies or for the first time in this extension study.

Official Title

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

Eligibility Criteria

Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Jeffrey Dunn, MD
Jeffrey Dunn, MD
Multiple sclerosis specialist, General neurologist
Clinical Professor, Neurology & Neurological Sciences

Contact us to find out if this trial is right for you.


Jeffrey Dunn, MD
(650) 736-4310